Human Growth Hormone (HGH) vs PT-141 (Bremelanotide)
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Human Growth Hormone (HGH)
Human Growth Hormone (somatropin) is a 191-amino acid protein identical to naturally produced GH. FDA-approved for growth hormone deficiency, Turner syndrome, and other conditions. Widely used off-label for anti-aging and performance.
Full details →PT-141 (Bremelanotide)
PT-141, also known as Bremelanotide, is a synthetic peptide analog of alpha-melanocyte-stimulating hormone. It is the only FDA-approved treatment for hypoactive sexual desire disorder (HSDD) in premenopausal women.
Full details →Side-by-Side Comparison
| Aspect | Human Growth Hormone (HGH) | PT-141 (Bremelanotide) |
|---|---|---|
| Dose Range | 200 mcg–2 mg | 1.8 mg |
| Frequency | 1x daily | Less than daily |
| Cycle Length | 12–24 weeks | 4–12 weeks |
| Route | subcutaneous | subcutaneous |
| Mechanism | Binds to GH receptors throughout the body, stimulating IGF-1 production in the liver. Promotes protein synthesis, fat metabolism, and cellular regeneration across multiple tissues. | PT-141 activates melanocortin receptors (MC3R and MC4R) in the central nervous system, particularly in areas associated with sexual arousal. Unlike PDE5 inhibitors, it works through the nervous system rather than the vascular system. |
| Typical Dosage | Medical: 0.1-0.3mg/kg/week divided into daily doses. Anti-aging: 1-2 IU daily. Performance: 2-6 IU daily, sometimes higher. | FDA-approved dose: 1.75mg administered subcutaneously at least 45 minutes before anticipated sexual activity. Not to be used more than once within 24 hours or more than 8 times per month. |
| Administration | Subcutaneous injection, preferably at night to mimic natural pulsatile release. Rotate injection sites. Store refrigerated. | Subcutaneous injection in the abdomen. Available as Vyleesi (commercial product). Research use may involve different dosing protocols. |
| Side Effects | Joint pain, water retention, carpal tunnel syndrome, potential insulin resistance, and acromegaly features with long-term high doses. | Common side effects include nausea (40% of users), flushing, headache, and injection site reactions. Transient blood pressure increases may occur. |
| Best For |
What They Have in Common
Human Growth Hormone (HGH), PT-141 (Bremelanotide) are both commonly used for:
Key Differences
Unique to Human Growth Hormone (HGH):
Which Has Stronger Evidence?
- Recovery & Healing: Human Growth Hormone (HGH) has stronger research support.
| Goal | Human Growth Hormone (HGH) | PT-141 (Bremelanotide) |
|---|---|---|
| Recovery & Healing | high | low |
Key Studies
Human Growth Hormone (HGH)
- Transgenic Artifacts Caused by Passenger Human Growth Hormone.
Trends in endocrinology and metabolism: TEM, 2018
- [Human growth hormone and Turner syndrome].
Anales de pediatria (Barcelona, Spain : 2003), 2017
- Significance of the disulphide bonds of human growth hormone.
Endokrynologia Polska, 2013
PT-141 (Bremelanotide)
- Small Effects, Questionable Outcomes: Bremelanotide for Hypoactive Sexual Desire Disorder.
Journal of sex research, 2024
- Safety Profile of Bremelanotide Across the Clinical Development Program.
Journal of women's health (2002), 2022
- Bremelanotide for Treatment of Female Hypoactive Sexual Desire.
Neurology international, 2022
Ready to Learn More?
Looking for trusted sources?